Lantheus Holdings (LNTH) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Lantheus Holdings (LNTH) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 14.04% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 8.71% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -34.81% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 14.78% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 36.74% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | -7.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.28% |
| Mar 31, 2026 | 253.53% |
| Dec 31, 2025 | 34.88% |
| Sep 30, 2025 | -23.17% |
| Jun 30, 2025 | 22.29% |
| Mar 31, 2025 | 19.30% |
| Dec 31, 2024 | 33.57% |
| Sep 30, 2024 | 127.48% |
| Jun 30, 2024 | 62.97% |
| Mar 31, 2024 | 144.13% |
| Dec 31, 2023 | 216.51% |
| Sep 30, 2023 | 182.99% |
| Jun 30, 2023 | 148.92% |
| Mar 31, 2023 | -41.63% |
| Dec 31, 2022 | -137.55% |
| Sep 30, 2022 | 132.76% |
| Jun 30, 2022 | 88.66% |
| Mar 31, 2022 | 62.84% |
| Dec 31, 2021 | -71.29% |
| Sep 30, 2021 | -51.06% |